Topic: How To Invest

Pat: Would you take a look at these two risky stocks, please? MannKind and SmartHeat. Thanks.

Article Excerpt

MannKind Corp., $2.82, symbol MNKD on Nasdaq (Shares outstanding: 121.7 million; Market cap: $365.4 million; www.mannkindcorp.com), aims to discover, develop and sell treatments for diabetes and cancer. In January 2011, MannKind reached a high of $10.05, but on January 19 it dropped to around $6 in one day after the U.S. Food and Drug Administration (FDA) failed to approve its inhaled insulin treatment, Afrezza. This drug appeared to offer advantages over injected insulin. This was the second time the FDA declined to approve Afrezza. The FDA has now told MannKind to conduct at least two more clinical studies before it resubmits Afrezza for approval. Under the best scenario, however, the company won’t be able to resubmit the drug for 15 to 16 months. The FDA would then need six more months to decide whether to approve Afrezza. In response to the rejection in January, MannKind cut 179 workers, or 41% its workforce, to focus on getting Afrezza approved. The company also terminated a..